Eli Lilly and Insilico Ink $2.75B AI Drug Deal

Eli Lilly and Insilico Medicine have signed a $2.75 billion research and licensing agreement to accelerate drug discovery ^[1][3]. The deal focuses on using generative AI to find and develop new oral therapeutics for various diseases ^[1][2]. This collaboration expands on a partnership between the two companies that originally began in 2023 ^[1][3]. The agreement involves milestones and royalties for Insilico as they identify potential drug candidates ^[2][3]. By leveraging Insilico’s proprietary AI platform, Lilly aims to shorten development timelines for complex treatments ^[1]. Both firms expect this technology to streamline the discovery process across multiple therapeutic areas ^[2].